Biote (BTMD) | Financial Analysis & Statements
Biote Corp. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
46.4M
Gross Profit
31.6M
68.03%
Operating Income
6.8M
14.72%
Net Income
2.6M
5.64%
EPS (Diluted)
$0.06
Balance Sheet Metrics
Total Assets
107.6M
Total Liabilities
158.0M
Shareholders Equity
-50.4M
Cash Flow Metrics
Operating Cash Flow
7.6M
Free Cash Flow
5.2M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Biote Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 192.2M | 197.2M | 185.4M | 165.0M | 139.4M |
| Cost of Goods Sold | 54.9M | 58.1M | 57.9M | 54.6M | 48.8M |
| Gross Profit | 137.4M | 139.1M | 127.5M | 110.4M | 90.6M |
| Gross Margin % | 71.5% | 70.5% | 68.8% | 66.9% | 65.0% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 101.8M | 107.4M | 98.8M | 171.1M | 54.0M |
| Other Operating Expenses | - | - | - | 974.0K | 2.1M |
| Total Operating Expenses | 101.8M | 107.4M | 98.8M | 172.1M | 56.0M |
| Operating Income | 35.6M | 31.6M | 28.7M | -60.7M | 34.6M |
| Operating Margin % | 18.5% | 16.0% | 15.5% | -36.8% | 24.8% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 11.0M | 11.0M | 6.4M | 4.0M | 1.7M |
| Other Non-Operating Income | 13.0M | -19.6M | -22.4M | 66.5M | 17.0K |
| Pre-tax Income | 37.6M | 1.0M | -123.0K | 1.7M | 32.9M |
| Income Tax | 6.0M | 970.0K | 2.7M | 388.0K | 286.0K |
| Effective Tax Rate % | 15.9% | 95.5% | 0.0% | 22.7% | 0.9% |
| Net Income | 31.6M | 46.0K | -2.8M | 1.3M | 32.6M |
| Net Margin % | 16.4% | 0.0% | -1.5% | 0.8% | 23.4% |
| Key Metrics | |||||
| EBITDA | 39.2M | 35.2M | 31.6M | -58.5M | 36.0M |
| EPS (Basic) | - | $0.09 | $0.13 | $-0.12 | $4.31 |
| EPS (Diluted) | - | $0.09 | $0.13 | $-0.12 | $4.31 |
| Basic Shares Outstanding | - | 34270809 | 25709343 | 8059371 | 7574271 |
| Diluted Shares Outstanding | - | 34270809 | 25709343 | 8059371 | 7574271 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Biote Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 24.1M | 39.3M | 89.0M | 79.2M | 26.8M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 6.9M | 7.6M | 6.8M | 6.9M | 5.2M |
| Inventory | 19.1M | 14.8M | 17.3M | 11.2M | 9.6M |
| Other Current Assets | 10.0K | 111.0K | 308.0K | - | 3.9M |
| Total Current Assets | 54.7M | 68.1M | 122.3M | 101.2M | 47.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.7M | 252.0K | 0 | 2.1M | 356.0K |
| Goodwill | 20.5M | 21.0M | 5.0M | 5.1M | 4.6M |
| Intangible Assets | 8.8M | 9.4M | 5.0M | 5.1M | 4.6M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 24.9M | 28.8M | 24.9M | 1.8M | 0 |
| Total Non-Current Assets | 52.9M | 54.2M | 33.0M | 10.5M | 7.2M |
| Total Assets | 107.6M | 122.4M | 155.3M | 111.6M | 54.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 6.8M | 5.8M | 4.2M | 4.1M | 4.3M |
| Short-term Debt | 6.8M | 6.8M | 6.6M | 6.4M | 5.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 18.5M | 24.7M | - | - | - |
| Total Current Liabilities | 45.0M | 51.5M | 22.2M | 18.8M | 17.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 103.1M | 104.1M | 108.3M | 114.0M | 32.1M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 8.8M | 67.4M | 60.0M | 32.1M | - |
| Total Non-Current Liabilities | 113.0M | 173.1M | 169.6M | 151.2M | 32.9M |
| Total Liabilities | 158.0M | 224.6M | 191.8M | 169.9M | 50.2M |
| Equity | |||||
| Common Stock | 4.0K | 4.0K | 6.0K | 6.0K | 0 |
| Retained Earnings | -49.5M | -100.3M | -29.4M | -44.5M | 4.2M |
| Treasury Stock | 9.0M | 5.6M | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -50.4M | -102.2M | -36.5M | -58.3M | 4.1M |
| Key Metrics | |||||
| Total Debt | 109.9M | 110.9M | 114.9M | 120.4M | 37.3M |
| Working Capital | 9.7M | 16.6M | 100.1M | 82.4M | 29.8M |
Balance Sheet Composition
Biote Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 31.6M | 46.0K | -2.8M | 1.3M | 32.6M |
| Depreciation & Amortization | 3.7M | 3.6M | 3.0M | 2.2M | 1.4M |
| Stock-Based Compensation | 8.9M | 8.7M | 9.1M | 82.2M | 0 |
| Working Capital Changes | -5.4M | 5.3M | -11.2M | -5.0M | -5.5M |
| Operating Cash Flow | 34.2M | 38.6M | 10.3M | 26.4M | 29.0M |
| Investing Activities | |||||
| Capital Expenditures | -5.0M | -6.4M | -359.0K | -333.0K | -1.4M |
| Acquisitions | 0 | -11.8M | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -5.0M | -18.3M | -359.0K | -333.0K | -1.4M |
| Financing Activities | |||||
| Share Repurchases | -3.4M | -5.6M | 0 | -424.0K | 0 |
| Dividends Paid | -1.7M | -4.7M | -8.7M | -12.9M | -11.4M |
| Debt Issuance | 5.0M | - | 0 | 125.0M | 0 |
| Debt Repayment | -6.2M | -6.2M | -6.2M | -40.6M | -5.0M |
| Financing Cash Flow | -43.8M | -78.5M | -14.8M | 70.7M | -20.3M |
| Free Cash Flow | 28.3M | 38.3M | 24.2M | -11.0M | 29.9M |
| Net Change in Cash | -14.6M | -58.1M | -4.9M | 96.8M | 7.2M |
Cash Flow Trend
Biote Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
3.08
Forward P/E
4.00
Price to Book
-1.39
Price to Sales
0.38
PEG Ratio
-0.06
Profitability Ratios
Profit Margin
14.07%
Operating Margin
9.40%
Return on Equity
-53.66%
Return on Assets
19.06%
Financial Health
Current Ratio
1.22
Debt to Equity
-2.18
Beta
1.29
Per Share Data
EPS (TTM)
$0.74
Book Value per Share
$-1.91
Revenue per Share
$6.14
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BTMD | 85.0M | 3.08 | -1.39 | -53.66% | 14.07% | -2.18 |
| HCA Healthcare | 106.0B | 16.86 | -38.44 | -244.82% | 8.97% | -17.57 |
| Tenet Healthcare | 16.5B | 12.17 | 3.88 | 27.02% | 6.60% | 160.79 |
| AirSculpt | 172.1M | 197.00 | 1.79 | -14.06% | -7.69% | 95.28 |
| Kindly MD | 150.2M | -17.25 | 98.19 | -763.28% | -177.03% | 43.58 |
| Joint | 126.0M | 66.00 | 8.06 | -1.50% | 5.30% | 13.33 |
Financial data is updated regularly. All figures are in the company's reporting currency.






